0 62

Cited 1 times in

Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

Authors
 Kyoungjune Pak  ;  Hae Kyung Shin  ;  Eun-Joo Kim  ;  Jae-Hyeok Lee  ;  Chul Hyoung Lyoo  ;  Jongsang Son  ;  Myung Jun Lee 
Citation
 Parkinsonism & Related Disorders, Vol.51 : 67-72, 2018 
Journal Title
 Parkinsonism & Related Disorders 
ISSN
 1353-8020 
Issue Date
2018
Keywords
(123)I-FP-CIT ; Body mass index ; Parkinson disease ; SPECT ; Weight loss
Abstract
INTRODUCTION: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. METHODS: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane (123I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. RESULTS: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10-3, p = 0.009; putamen, estimate = 7.04 × 10-3, p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10-3, p = 0.008; putamen, estimate = 2.34 × 10-3, p = 0.025). CONCLUSION: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.
Full Text
https://www.sciencedirect.com/science/article/pii/S135380201830110X
DOI
10.1016/j.parkreldis.2018.02.044
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실)
Yonsei Authors
류철형(Lyoo, Chul Hyoung) ORCID logo https://orcid.org/0000-0003-2231-672X
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/163761
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse